CytoDyn (CYDY) Other financing activities (2012 - 2025)

CytoDyn's (CYDY) quarterly Other financing activities came in at $21000.0 in Q3 2025, down 98.02% on a QoQ basis from $1.1 million in Q2 2025.

CytoDyn (CYDY) Other financing activities (2012 - 2025) Analysis & Trends

CytoDyn (CYDY) has 13 years of Other financing activities data on file, last reported at $21000.0 in Q3 2025.

Quarterly Other financing activities changed N/A year-over-year to $21000.0 in Q3 2025, while the trailing twelve-month figure through Feb 2026 was $1.1 million (changed N/A YoY) and the FY2025 annual result came in at $1.1 million, up 260.33% from the prior year.
Other financing activities fell to $21000.0 in Q3 2025, from $1.1 million in the prior quarter.
In the past five years, Other financing activities ranged from a high of $3.4 million in Q1 2021 to a low of -$16.8 million in Q2 2021.
A 4-year average of -$642833.3 and a median of $401500.0 in 2021 frame the typical range for Other financing activities.
Annual changes were most pronounced in 2021 — Other financing activities tumbled 211.24% — and 2022, when it soared 1958.41%.
Tracing CYDY's Other financing activities over 4 years: stood at -$113000.0 in 2021, then soared by 1958.41% to $2.1 million in 2022, then sank by 85.71% to $300000.0 in 2023, then plunged by 93.0% to $21000.0 in 2025.
The last three Other financing activities figures came in at $21000.0 (Q3 2025), $1.1 million (Q2 2025), and $300000.0 (Q3 2023), per Business Quant data.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn
4	Revolution Medicines	43.64 Bn	43.64 Bn	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn
7	Royalty Pharma	33.72 Bn	35.84 Bn	-
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn
10	CytoDyn	258.01 Mn	258.01 Mn	-

Download Data